SOTIO Biotech: SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab

BASEL, Jan. 19, 2023, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa

Related Keywords

Leuven ,Region Flamande ,Belgium ,Kostenloser Wertpapierhandel ,Richard Sachse ,Karen Geboes ,Eric Van Cutsem ,Michael Tattory ,Richard Kapsa ,University Hospital In Leuven Belgium ,Gent University Hospital Belgium ,Lifesci Communications ,Department Of Gastrointestinal ,Superagonist Technology ,Gent University Hospital ,Professor Karen Geboes ,Digestive Oncology ,University Hospital ,Sotio ,Biotech ,Doses ,First ,Patient ,Aurelio ,Hase ,Trial ,Anrilkefusp ,Alfa ,Combination ,Etuximab ,